OC-0250: Hadrontherapy as re-irradiation using active beam delivery at CNAO
Radiotherapy and Oncology
data on 138 children (78 males, 60 females, aged 0.9-17.9 years (median 5.7 years)) were prospectively collected in KiProReg at WPE. Diagnoses were CNS tumours (n=73), sarcomas (n=59), extracranial germ cell tumors (n=3) and others (n=3), respectively. Treatment sites were brain (n=72), head and neck including base of skull (n=38), spine (n=15), or pelvis (n=13). In 73.9% of the patients, macroscopic residual disease was present before PT. The median total dose of PT was 54.0 Gy (range
... Gy (range 29.8-74.0 Gy). Only two patients had a mixed beam technique. Due to the very young age, sedation was necessary in 55.1% of children. Concurrent chemotherapy was applied in 54.3% of children. Side-effects were classified according to Common Terminology Criteria for Adverse Events (CTCAE) V4.0 grading system. Results: Median follow-up (FU) since first diagnosis was 1.2 years (range 0.3-16.3 years). PT was well tolerated. No or only mild to moderate acute side-effects (grade 1 to 2) were documented in the majority of children (n=116). During PT, acute grade 3 side-effects were observed for blood/bone marrow (n=21), gastrointestinum (n=8) or as general disorders (n=3) as well as anorexia (n=1) when compared to baseline. Acute grade 4 side-effects during PT were only seen for blood/bone marrow (n=9). In 77 children, information on toxicity three months after PT is available. Only few patients presented with grade 3 or 4 toxicities, predominantly for blood/bone marrow (grade 3 n=7, grade 4 n=2). Seven of them had received chemotherapy after PT. So far, 17 patients failed due to recurrence or progression (local n=5; systemic n=12). Six of them (4.3%) have died so far, all due to disease.